Asthma Rescue Medication Airsupra is Now Available
Airsupra is an anti-inflammatory rescue medication that can treat the symptoms of asthma while helping to prevent an attack.
AstraZeneca has launched Airsupra (albuterol/budesonide) as an as-needed treatment to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler combination rescue medication containing albuterol, a short-acting beta2-agonist, and budesonide, an anti-inflammatory inhaled corticosteroid. It was developed by AstraZeneca and Avillion.
A spokesperson for AstraZeneca would not provide a price for Airsupra but said the price reflects the value of the product. AstraZeneca is offering a copay assistance program where eligible commercially insured patients may pay as little as $0. For patients with commercial insurance who do not cover Airsupra or who have restriction such step-edit, prior authorization, or NDC block, they may be able to pay as low as $15 for each inhaler. The copay program is managed by ConnectiveRx.
Airsupra is now covered on the national formularies of the three largest commercial PBMs: by Express Scripts, CVS Caremark, and Optum/United Healthcare, according to the AstraZeneca spokesperson.
Priya Bansal, M.D.
“For more than five decades, the medical community has used SABA-only (short-acting beta agonist) rescue, which does not address the inflammatory component of asthma,” Priya Bansal, M.D., CEO, Asthma and Allergy Wellness Center in St. Charles, Ill., said in a press release. “The MANDALA study has demonstrated how these patients can benefit from an as-needed anti-inflammatory rescue to treat their symptoms while helping to prevent an attack even if they are on inhaled corticosteroid-containing maintenance therapy.
Airsupra was approved in January 2023 based on results from the MANDALA and DENALI phase 3 trials. In MANDALA, Airsupra significantly reduced the risk of severe exacerbations compared with albuterol in patients with moderate to severe asthma when used as an as-needed rescue medication in response to symptoms.
In the secondary endpoint of mean annualized total systemic corticosteroid exposure, Airsupra demonstrated a significant reduction compared with albuterol at the approved dose of 180mcg albuterol/160mcg budesonide. In DENALI, Airsupra significantly improved lung function compared were the individual components albuterol and budesonide in patients with mild-to-moderate asthma.
Results from the MANDALA trial were published in the New England Journal of Medicine in May 2022.
Remote Care Advancement for Heart Failure, COPD and Diabetes Patients
February 24th 2021In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
